Latest Articles

Publication Date
Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial.

Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …

Published: Sept. 5, 2026, midnight
Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies.

Endometriosis is frequently managed with hormonal suppression that can induce hypoestrogenism during a period when many patients are still accruing peak bone mass. This narrative review summarizes current clinical and …

Published: Aug. 19, 2026, midnight
Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review.

In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly widespread demand for effective long-term medical therapies. The objective of …

Published: Aug. 14, 2026, midnight
Hormonal therapies for endometriosis-associated pain: inflammatory limitations and pharmacological challenges.

Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …

Published: Aug. 11, 2026, midnight
When It's Not Just "That Time of the Month": Identifying Thoracic Endometriosis in the Context of Recurrent Pleural Effusion.

Recurrent hemorrhagic pleural effusion presents as a challenge for both the clinician and the patient, with common causes being tuberculosis, malignancy, and collagen vascular diseases. Among uncommon causes of recurrent …

Published: Aug. 4, 2026, midnight
Pulmonary alveolar proteinosis diagnosed during leuprorelin acetate therapy for ovarian endometrioma: a case report.

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder characterized by impaired surfactant clearance due to alveolar macrophage dysfunction. Leuprorelin acetate, a gonadotropin-releasing hormone agonist, is widely used in the …

Published: July 17, 2026, midnight
Clinical features and reproductive outcomes after first frozen embryo transfer in patients with different ultrasound-diagnosed adenomyosis subtypes following ultralong gonadotropin-releasing hormone agonist pretreatment: a retrospective cohort study.

The differences between adenomyosis subtypes in clinical features and reproductive outcomes remain largely unexplored. This study aimed to compare clinical features and reproductive outcomes after the first frozen embryo transfer …

Published: July 11, 2026, midnight
The Microbiome-Gut-Gonad Axis: How Microbial Metabolites Orchestrate Reproductive Physiology, Pathology, and Therapy.

The human microbiome, a dynamic endocrine organ, exerts profound systemic influence through the production of bioactive metabolites. While the microbiome-gut-brain axis is well-established, the direct conduit between the gut microbiota …

Published: July 4, 2026, midnight
The evaluation of pharmacotherapy in endometriosis: changes, challenges and difficulties.

Endometriosis presents a multitude of challenges for individuals. Current treatment of the disease is based on pharmacotherapy that aims to relieve pain, improves future fertility, potentially slows disease progression and …

Published: July 1, 2026, midnight
Vitamin D3 promotes regression of endometrial implants comparable to buserelin in a rat model of endometriosis.

Buserelin, a gonadotropin-releasing hormone agonist, reduces gonadotropin and estrogen levels and is commonly used to alleviate the symptoms of endometriosis. Vitamin D3 has been reported to exhibit anti-inflammatory and pro-apoptotic …

Published: June 30, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!